A Phase 4 interventional study of Nirsevimab in RSV Immunization, sponsored by Sanofi. Active, not recruiting at 7 sites in India. Open to participants aged 0 Months to 24 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-23.
Sponsored by Sanofi · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to describe the safety and efficacy outcomes associated with the use of nirsevimab, administered as per routine clinical practice, in neonates and infants aged 0 to 12 months born during or entering their first RSV season and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
Study duration: up to 16 months, including 10 months of enrollment and 6 months of follow-up
Visit frequency:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Neonates and infants aged 0 to 12 months on the day of inclusion and born during or entering their first RSV season OR children up to 24 months of age on the day of inclusion who remain vulnerable to severe RSV disease through their second RSV season
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive: * 1 intramuscular (IM) injection for neonates and infants aged 0 to 12 months born or entering their first RSV season at Day 01 * 2 IM injections for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season at Day 01
Biological: Nirsevimab
Pharmaceutical form:Sterile solution for injection-Route of administration:Intramuscular
Also known as: 526, Beyfortus®
Presence of immediate adverse events (AEs)
Number of participants experiencing immediate AEs
Time frame: Within 30 minutes after immunization
Presence of non-serious AEs
Number of participants experiencing non-serious AEs
Time frame: From Day 01 through Day 31
Presence of adverse events of special interest (AESIs) throughout the study
Number of participants experiencing AESIs
Time frame: Throughout the study (approximately 6 months)
Presence of medically attended adverse events (MAAEs) throughout the study
Number of participants experiencing MAAEs
Time frame: Throughout the study (approximately 6 months)
Presence of serious adverse events (SAEs) throughout the study
Number of participants experiencing SAEs
Time frame: Throughout the study (approximately 6 months)
Incidence of medically attended lower respiratory tract infection (LRTI) (outpatient and inpatient) due to reverse transcription--polymerase chain reaction (RT-PCR) confirmed RSV
Incidence of medically attended LRTI (outpatient and inpatient) due to reverse transcription--polymerase chain reaction (RT-PCR) confirmed RSV
Time frame: Through 180 days after dosing
Incidence of LRTI hospitalizations due to RT-PCR confirmed RSV through 180 days after dosing
Incidence of LRTI hospitalizations due to RT-PCR confirmed RSV through 180 days after dosing
Time frame: Through 180 days after dosing
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Started Jul 2025 (actual). Primary completion is estimated for Jun 2026, 10 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nirsevimab